We are live on ! Find out more
MIM

MetLife Investment Management Portfolio holdings

AUM $19.6B
1-Year Est. Return 32.64%
This Fund
S&P 500
This Quarter Est. Return
+10.56%
1 Year Est. Return
+32.64%
3 Year Est. Return
+107.14%
5 Year Est. Return
+140.16%
10 Year Est. Return
–
AUM
$12.2B
AUM Growth
+$1.03B
Cap. Flow
+$49.2M
Cap. Flow %
0.4%
Top 10 Hldgs %
25.44%
Holding
2,628
New
63
Increased
565
Reduced
814
Closed
130

Top Buys

Rank Stock Value
1
LQD icon
iShares iBoxx $ Investment Grade Corporate Bond ETF
LQD
+$379M
2
IWM icon
iShares Russell 2000 ETF
IWM
+$14.1M
3
IJH icon
iShares Core S&P Mid-Cap ETF
IJH
+$12.6M
4
EPAM icon
EPAM Systems
EPAM
+$8.07M
5
AA icon
Alcoa
AA
+$4.54M

Top Sells

Rank Stock Value
1
EPD icon
Enterprise Products Partners
EPD
+$31.9M
2
SPY icon
State Street SPDR S&P 500 ETF Trust
SPY
+$31.2M
3
MDY icon
State Street SPDR S&P MIDCAP 400 ETF Trust
MDY
+$28.5M
4
MMP
Magellan Midstream Partners, L.P.
MMP
+$20.9M
5
AAPL icon
Apple
AAPL
+$14.5M

Sector Composition

Rank Sector Weight
1 Technology 22.34%
2 Healthcare 12.24%
3 Financials 12%
4 Consumer Discretionary 11.44%
5 Industrials 8.69%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SYRE icon
2551
Spyre Therapeutics
SYRE
$9.18B
– –
-614
Closed -$122K
TXMD icon
2552
TherapeuticsMD
TXMD
$24.1M
– –
-2,972
Closed -$110K
URGN icon
2553
UroGen Pharma
URGN
$2.39B
– –
-7,354
Closed -$124K
VHC icon
2554
VirnetX Holding Corp
VHC
$65.8M
– –
-1,147
Closed -$89.9K
VRA icon
2555
Vera Bradley
VRA
$96.7M
– –
-9,645
Closed -$90.8K
XBIT icon
2556
XBiotech
XBIT
$75M
– –
-5,892
Closed -$76.3K
ZVRA icon
2557
Zevra Therapeutics
ZVRA
$679M
– –
-2,415
Closed -$22.5K
ZYXI
2558
DELISTED
Zynex
ZYXI
– –
-8,281
Closed -$85.7K
NEUE
2559
DELISTED
NeueHealth
NEUE
– –
-260
Closed -$170K
LENZ
2560
LENZ Therapeutics
LENZ
$158M
– –
-980
Closed -$112K
QTTB icon
2561
Q32 Bio
QTTB
$458M
– –
-874
Closed -$124K
TECX
2562
Tectonic Therapeutic
TECX
$720M
– –
-1,221
Closed -$81.8K
NAGE
2563
Niagen Bioscience
NAGE
$242M
– –
-5,907
Closed -$37K
SYRS
2564
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
– –
-2,170
Closed -$97K
VIRX
2565
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
– –
-5,069
Closed -$40.7K
NEXI
2566
DELISTED
NexImmune, Inc. Common Stock
NEXI
– –
-308
Closed -$117K
AWH
2567
DELISTED
Aspira Women's Health Inc. Common Stock
AWH
– –
-300
Closed -$14.6K
CBAY
2568
DELISTED
Cymabay Therapeutics
CBAY
– –
-26,489
Closed -$96.7K
BFX
2569
DELISTED
BowFlex Inc.
BFX
– –
-3,518
Closed -$32.8K
SIEN
2570
DELISTED
Sientra, Inc.
SIEN
– –
-959
Closed -$55K
LTRPA
2571
DELISTED
Liberty TripAdvisor Holdings, Inc. Series A
LTRPA
– –
-26,991
Closed -$83.4K
EBET
2572
DELISTED
EBET, INC. Common Stock
EBET
– –
-153
Closed -$154K
MMP
2573
DELISTED
Magellan Midstream Partners, L.P.
MMP
– –
-459,482
Closed -$20.9M
INFI
2574
DELISTED
Infinity Pharmaceuticals, Inc.
INFI
– –
-33,123
Closed -$113K
FXLV
2575
DELISTED
F45 Training Holdings Inc.
FXLV
– –
-8,740
Closed -$131K
101 102
103
104 105

Similar funds

SPIA
Steward Partners Investment Advisory New York $19.6B AUM 22.89% 1-Year Est. Return
Select Equity Group
Select Equity Group New York $19.5B AUM 17.33% 1-Year Est. Return
BG
Bahl & Gaynor Cincinnati, Ohio $19.8B AUM 19.53% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return
HHII
H&H International Investment Palo Alto, California $20B AUM 9.66% 1-Year Est. Return
LF
Lansforsakringar Fondforvaltning Stockholm, Sweden $19.1B AUM 26.9% 1-Year Est. Return
EIM
Elliott Investment Management West Palm Beach, Florida $20.1B AUM 60.76% 1-Year Est. Return

MetLife Investment Management's Q4 2021 Portfolio in Review

As of Q4 2021, MetLife Investment Management held 2,628 positions worth $12.2B, up 9.2% from $11.2B the previous quarter. Its ten largest holdings account for 25% of the portfolio.

MetLife Investment Management's Q4 2021 filing shows 63 new, 565 increased, 814 reduced and 130 closed positions. Its largest new stake was iShares iBoxx $ Investment Grade Corporate Bond ETF: 2,855,000 shares worth $378M. The largest sale was Enterprise Products Partners, an estimated $31.9M.

By sector, the portfolio is most concentrated in Technology at 22% of assets, up from 21% a quarter earlier, followed by Healthcare and Financials.

  • MetLife Investment Management's largest Q4 2021 buy was iShares iBoxx $ Investment Grade Corporate Bond ETF: 2,855,000 shares worth $378M.
  • MetLife Investment Management added most to iShares Russell 2000 ETF in Q4 2021, an estimated $14.1M increase.
  • MetLife Investment Management's biggest Q4 2021 reduction was State Street SPDR S&P 500 ETF Trust, cutting an estimated $31.2M.
  • MetLife Investment Management fully exited Enterprise Products Partners in Q4 2021, selling an estimated $31.9M.
  • MetLife Investment Management's ten largest holdings make up 25% of its $12.2B portfolio in Q4 2021.
  • MetLife Investment Management opened 63 new positions and closed 130 in Q4 2021.
  • MetLife Investment Management's portfolio value rose 9.2% quarter-over-quarter to $12.2B.

Based on MetLife Investment Management's 13F filing for Q4 2021, filed 15 Feb 2022.